What's Happening?
The Broad Institute, Boston Children's Hospital, and The Jackson Laboratory have launched the Center for Therapeutic Genetics (CTG) to develop genetic medicines for rare and ultra-rare diseases. The collaboration aims to create precision medicines using
advanced genetic editing techniques like base and prime editing. The center will focus on making these treatments scalable and accessible, sharing methods and data to facilitate broader application.
Why It's Important?
This initiative addresses the significant gap in treatment options for rare diseases, which affect millions globally but often lack approved therapies. By focusing on scalable and repeatable genetic treatments, the CTG aims to revolutionize the approach to rare diseases, potentially reducing costs and increasing accessibility. This could lead to significant advancements in personalized medicine and improve outcomes for patients with rare conditions.
What's Next?
The CTG plans to expand its collaborative efforts, working with regulatory bodies to establish frameworks for these novel treatments. The center will also focus on developing treatments for specific genetic conditions, supported by significant funding. As the center evolves, it aims to set a new standard in genetic medicine, potentially influencing policy and practice in the field.
